

4. (original) The pharmaceutical paclitaxel composition of claim 1, wherein said acid is a mineral acid.
5. (original) The pharmaceutical paclitaxel composition of claim 3, wherein said acid is citric acid.
6. (original) The pharmaceutical paclitaxel composition of claim 5, wherein said citric acid is monohydrous.
7. (original) The pharmaceutical paclitaxel composition of claim 5, wherein the citric acid is hydrous.
8. (original) The pharmaceutical paclitaxel composition of claim 5, wherein the citric acid is anhydrous.
9. (original) The pharmaceutical paclitaxel composition of claim 3, wherein said acid is acetic acid.
10. (original) The pharmaceutical paclitaxel composition of claim 2, wherein said acid is an organic acid.
11. (original) The pharmaceutical paclitaxel composition of claim 2, wherein said acid is a mineral acid.
12. (original) The pharmaceutical paclitaxel composition of claim 10, wherein said acid is citric acid.
13. (original) The pharmaceutical paclitaxel composition of claim 10, wherein said citric acid is monohydrous.
14. (original) The pharmaceutical paclitaxel composition of claim 10, wherein the citric acid is hydrous.

15. (original) The pharmaceutical paclitaxel composition of claim 10, wherein the citric acid is anhydrous.
16. (original) The pharmaceutical paclitaxel composition of claim 10, wherein said acid is acetic acid.
17. (original) An article of manufacture comprising a sealed container and a pharmaceutical paclitaxel composition disposed within said sealed container, said pharmaceutical paclitaxel composition comprising:
paclitaxel;
a pharmaceutically-acceptable carrier; and
an acid; said composition being such that at least 96.6% of the paclitaxel potency is retained when said composition is stored at 40°C for seven days.
18. (original) An article of manufacture of claim 17, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.
19. (original) The article of manufacture of claim 18, wherein said pharmaceutically-acceptable carrier further comprises ethanol.
20. (original) The article of manufacture of claim 17, wherein said acid is an organic acid.
21. (original) The article of manufacture of claim 17, wherein said acid is a mineral acid.
22. (original) The article of manufacture of claim 20, wherein said acid is acetic acid.
23. (original) The article of manufacture of claim 20, wherein said acid is citric acid.
24. (original) The article of manufacture of claim 23, wherein said citric acid is anhydrous.
25. (original) The article of manufacture of claim 23, wherein said citric acid is monohydrous.

26. (original) The article of manufacture of claim 23, wherein said citric acid is hydrous.
27. (original) The article of manufacture of claim 18, wherein said acid is an organic acid.
28. (original) The article of manufacture of claim 18, wherein said acid is a mineral acid.
29. (original) The article of manufacture of claim 27, wherein said acid is acetic acid.
30. (original) The article of manufacture of claim 27, wherein said acid is citric acid.
31. (original) The article of manufacture of claim 30, wherein said citric acid is anhydrous.
32. (original) The article of manufacture of claim 30, wherein said citric acid is monohydrous.
33. (original) The article of manufacture of claim 30, wherein said citric acid is hydrous.
34. (original) The article of manufacture of claim 19, wherein said acid is an organic acid.
35. (original) The article of manufacture of claim 19, wherein said acid is a mineral acid.
36. (original) The article of manufacture of claim 34, wherein said acid is acetic acid.
37. (original) The article of manufacture of claim 34, wherein said acid is citric acid.
38. (original) The article of manufacture of claim 37, wherein said citric acid is anhydrous.
39. (original) The article of manufacture of claim 37, wherein said citric acid is monohydrous.
40. (original) The article of manufacture of claim 37, wherein said citric acid is hydrous.

5

Docket No. NPB-100D5
Serial No. 09/970,558

41. (original) An article of manufacture produced by the process of:

- (a) obtaining a sealable container;
- (b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid; said formulation being such that at least 96.6% of the paclitaxel potency is retained when the formulation is stored at 40°C for seven days;
- (c) placing said pharmaceutical formulation in said sealable container;
- (d) sealing said sealable container; and
- (e) storing said pharmaceutical formulation in said sealed container for at least seven days.

42. (original) The article of manufacture of claim 41, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.

43. (original) The article of manufacture of claim 42, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

44. (original) The article of manufacture of claim 41, wherein said acid is an organic acid.

45. (original) The article of manufacture of claim 41, wherein said acid is a mineral acid.

46. (original) The article of manufacture of claim 44, wherein said acid is acetic acid.

47. (original) The article of manufacture of claim 44, wherein said acid is citric acid.

48. (original) The article of manufacture of claim 47, wherein said citric acid is anhydrous.

49. (original) The article of manufacture of claim 47, wherein said citric acid is monohydrous.

50. (original) The article of manufacture of claim 47, wherein said citric acid is hydrous.

51. (original) The article of manufacture of claim 42, wherein said acid is an organic acid.

6

Docket No. NPB-100D5
Serial No. 09/970,558

52. (original) The article of manufacture of claim 42, wherein said acid is a mineral acid.
53. (original) The article of manufacture of claim 51, wherein said acid is acetic acid.
54. (original) The article of manufacture of claim 51, wherein said acid is citric acid.
55. (original) The article of manufacture of claim 54, wherein said citric acid is anhydrous.
56. (original) The article of manufacture of claim 54, wherein said citric acid is monohydrous.
57. (original) The article of manufacture of claim 54, wherein said citric acid is hydrous.
58. (original) The article of manufacture of claim 43, wherein said acid is an organic acid.
59. (original) The article of manufacture of claim 43, wherein said acid is a mineral acid.
60. (original) The article of manufacture of claim 58, wherein said acid is acetic acid.
61. (original) The article of manufacture of claim 58, wherein said acid is citric acid.
62. (original) The article of manufacture of claim 61, wherein said citric acid is anhydrous.
63. (original) The article of manufacture of claim 61, wherein said citric acid is monohydrous.
64. (original) The article of manufacture of claim 61, wherein said citric acid is hydrous.
65. (original) A pharmaceutical paclitaxel composition which is at least seven days old, comprising:
paclitaxel;
a pharmaceutically-acceptable carrier; and
an acid; said at least seven-day old composition being such that at least 96.6% of the original

paclitaxel potency is retained when said composition is stored at 40°C for seven days, and said at least seven-day old composition having at least 96.6% of its original paclitaxel potency.

66. (original) A pharmaceutical paclitaxel composition according to claim 65, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.

67. (original) A pharmaceutical paclitaxel composition of claim 66, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

68. (original) A pharmaceutical paclitaxel composition of claim 65, wherein said acid is an organic acid.

69. (original) A pharmaceutical paclitaxel composition of claim 65, wherein said acid is a mineral acid.

70. (original) A pharmaceutical paclitaxel composition of claim 68, wherein said acid is acetic acid.

71. (original) A pharmaceutical paclitaxel composition of claim 68, wherein said acid is citric acid.

72. (original) A pharmaceutical paclitaxel composition of claim 71, wherein said citric acid is anhydrous.

73. (original) A pharmaceutical paclitaxel composition of claim 71, wherein said citric acid is monohydrous.

74. (original) A pharmaceutical paclitaxel composition of claim 71, wherein said citric acid is hydrous.

75. (original) A pharmaceutical paclitaxel composition of claim 66, wherein said acid is an organic acid.

76. (original) A pharmaceutical paclitaxel composition of claim 66, wherein said acid is a mineral acid.
77. (original) A pharmaceutical paclitaxel composition of claim 75, wherein said acid is acetic acid.
78. (original) A pharmaceutical paclitaxel composition of claim 75, wherein said acid is citric acid.
79. (original) A pharmaceutical paclitaxel composition of claim 78, wherein said citric acid is anhydrous.
80. (original) A pharmaceutical paclitaxel composition of claim 78, wherein said citric acid is monohydrous.
81. (original) A pharmaceutical paclitaxel composition of claim 78, wherein said citric acid is hydrous.
82. (original) A pharmaceutical paclitaxel composition of claim 67, wherein said acid is an organic acid.
83. (original) A pharmaceutical paclitaxel composition of claim 67, wherein said acid is a mineral acid.
84. (original) A pharmaceutical paclitaxel composition of claim 82, wherein said acid is acetic acid.
85. (original) A pharmaceutical paclitaxel composition of claim 82, wherein said acid is citric acid.
86. (original) A pharmaceutical paclitaxel composition of claim 85, wherein said citric acid is anhydrous.
87. (original) A pharmaceutical paclitaxel composition of claim 85, wherein said citric acid is monohydrous.

88. (original) A pharmaceutical paclitaxel composition of claim 85, wherein said citric acid is hydrous.

89. (original) A pharmaceutical paclitaxel composition which is at least seven days old, comprising: paclitaxel;

a pharmaceutically-acceptable carrier; and

an acid; said at least seven-day old composition being such that the composition comprises no more than 2.3% total impurities when said composition is stored at 40°C for seven days, and wherein said composition comprises no more than 2.3% total impurities.

90. (original) A pharmaceutical paclitaxel composition according to claim 89, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.

91. (original) A pharmaceutical paclitaxel composition of claim 90, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

92. (original) A pharmaceutical paclitaxel composition of claim 89, wherein said acid is an organic acid.

93. (original) A pharmaceutical paclitaxel composition of claim 89, wherein said acid is a mineral acid.

94. (original) A pharmaceutical paclitaxel composition of claim 92, wherein said acid is acetic acid.

95. (original) A pharmaceutical paclitaxel composition of claim 92, wherein said acid is citric acid.

96. (original) A pharmaceutical paclitaxel composition of claim 95, wherein said citric acid is anhydrous.

97. (original) A pharmaceutical paclitaxel composition of claim 95, wherein said citric acid is monohydrous.

10

Docket No. NPB-100D5
Serial No. 09/970,558

98. (original) A pharmaceutical paclitaxel composition of claim 95, wherein said citric acid is hydrous.

99. (original) A pharmaceutical paclitaxel composition of claim 90, wherein said acid is an organic acid.

100. (original) A pharmaceutical paclitaxel composition of claim 90, wherein said acid is a mineral acid.

101. (original) A pharmaceutical paclitaxel composition of claim 99, wherein said acid is acetic acid.

102. (original) A pharmaceutical paclitaxel composition of claim 99, wherein said acid is citric acid.

103. (original) A pharmaceutical paclitaxel composition of claim 102, wherein said citric acid is anhydrous.

104. (original) A pharmaceutical paclitaxel composition of claim 102, wherein said citric acid is monohydrous.

105. (original) A pharmaceutical paclitaxel composition of claim 102, wherein said citric acid is hydrous.

106. (original) A pharmaceutical paclitaxel composition of claim 91, wherein said acid is an organic acid.

107. (original) A pharmaceutical paclitaxel composition of claim 91, wherein said acid is a mineral acid.

108. (original) A pharmaceutical paclitaxel composition of claim 106, wherein said acid is acetic

11

Docket N . NPB-100D5
Serial No. 09/970,558

acid.

109. (original) A pharmaceutical paclitaxel composition of claim 106, wherein said acid is citric acid.

110. (original) A pharmaceutical paclitaxel composition of claim 109, wherein said citric acid is anhydrous.

111. (original) A pharmaceutical paclitaxel composition of claim 109, wherein said citric acid is monohydrous.

112. (original) A pharmaceutical paclitaxel composition of claim 109, wherein said citric acid is hydrous.

113. (original) An article of manufacture which is at least seven days old, comprising a sealed container and a pharmaceutical paclitaxel composition disposed within said sealed container, said composition comprising:

paclitaxel;

a pharmaceutically-acceptable carrier; and

an acid; said at least seven-day old composition being such that at least 96.6% of the original paclitaxel potency is retained when said composition is stored at 40°C for seven days, and said at least seven-day old composition having at least 96.6% of its original paclitaxel potency.

114. (original) An article of manufacture according to claim 113, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.

115. (original) The article of manufacture according to claim 114, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

116. (original) An article of manufacture of claim 113, wherein said acid is an organic acid.

12

Docket No. NPB-100D5
Serial No. 09/970,558

117. (original) An article of manufacture of claim 113, wherein said acid is a mineral acid.
118. (original) An article of manufacture of claim 116, wherein said acid is acetic acid.
119. (original) An article of manufacture of claim 116, wherein said acid is citric acid.
120. (original) An article of manufacture of claim 119, wherein said citric acid is anhydrous.
121. (original) An article of manufacture of claim 119, wherein said citric acid is monohydrous.
122. (original) An article of manufacture of claim 119, wherein said citric acid is hydrous.
123. (original) An article of manufacture of claim 114, wherein said acid is an organic acid.
124. (original) An article of manufacture of claim 114, wherein said acid is a mineral acid.
125. (original) An article of manufacture of claim 123, wherein said acid is acetic acid.
126. (original) An article of manufacture of claim 123, wherein said acid is citric acid.
127. (original) An article of manufacture of claim 126, wherein said citric acid is anhydrous.
128. (original) An article of manufacture of claim 126, wherein said citric acid is monohydrous.
129. (original) An article of manufacture of claim 126, wherein said citric acid is hydrous.
130. (original) An article of manufacture of claim 115, wherein said acid is an organic acid.
131. (original) An article of manufacture of claim 115, wherein said acid is a mineral acid.
132. (original) An article of manufacture of claim 130, wherein said acid is acetic acid.

13

Docket No. NPB-100D5

Serial No. 09/970,558

133. (original) An article of manufacture of claim 130, wherein said acid is citric acid.
134. (original) An article of manufacture of claim 133, wherein said citric acid is anhydrous.
135. (original) An article of manufacture of claim 133, wherein said citric acid is monohydrous.
136. (original) An article of manufacture of claim 133, wherein said citric acid is hydrous.
137. (original) An article of manufacture which is at least seven days old, comprising a sealed container and a pharmaceutical paclitaxel composition disposed within said sealed container, said composition comprising:
paclitaxel;
a pharmaceutically-acceptable carrier; and
an acid; such that said composition comprises no more than 2.3% total impurities when stored at 40°C for seven days, and wherein said composition comprises no more than 2.3% total impurities.
138. (original) An article of manufacture according to claim 137, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.
139. (original) The article of manufacture according to claim 138, wherein said pharmaceutically-acceptable carrier further comprises ethanol.
140. (original) An article of manufacture of claim 137, wherein said acid is an organic acid.
141. (original) An article of manufacture of claim 137, wherein said acid is a mineral acid.
142. (original) An article of manufacture of claim 140, wherein said acid is acetic acid.
143. (original) An article of manufacture of claim 140, wherein said acid is citric acid.
144. (original) An article of manufacture of claim 143, wherein said citric acid is anhydrous.

14

Docket No. NPB-100D5
Serial No. 09/970,558

145. (original) An article of manufacture of claim 143, wherein said citric acid is monohydrous.
146. (original) An article of manufacture of claim 143, wherein said citric acid is hydrous.
147. (original) An article of manufacture of claim 138, wherein said acid is an organic acid.
148. (original) An article of manufacture of claim 138, wherein said acid is a mineral acid.
149. (original) An article of manufacture of claim 147, wherein said acid is acetic acid.
150. (original) An article of manufacture of claim 147, wherein said acid is citric acid.
151. (original) An article of manufacture of claim 150, wherein said citric acid is anhydrous.
152. (original) An article of manufacture of claim 150, wherein said citric acid is monohydrous.
153. (original) An article of manufacture of claim 150, wherein said citric acid is hydrous.
154. (original) An article of manufacture of claim 139, wherein said acid is an organic acid.
155. (original) An article of manufacture of claim 139, wherein said acid is a mineral acid.
156. (original) An article of manufacture of claim 154, wherein said acid is acetic acid.
157. (original) An article of manufacture of claim 154, wherein said acid is citric acid.
158. (original) An article of manufacture of claim 157, wherein said citric acid is anhydrous.
159. (original) An article of manufacture of claim 157, wherein said citric acid is monohydrous.
160. (original) An article of manufacture of claim 157, wherein said citric acid is hydrous.

15

Docket No. NPB-100D5
Serial No. 09/970,558

161-208 (canceled)

209. (original) An article of manufacture produced by the process of:

- (a) obtaining a sealable container;
 - (b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid; said formulation being such that at least 96.6% of the paclitaxel potency is retained when the formulation is stored at 40°C for seven days;
 - (c) placing said pharmaceutical formulation in said sealable container;
 - (d) sealing said sealable container; and
 - (e) storing said pharmaceutical formulation in said sealed container for at least seven days;
- wherein said pharmaceutical formulation retains at least 96.6% of the original paclitaxel potency.

210. (original) The article of manufacture of claim 209, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.

211. (original) The article of manufacture of claim 210, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

212. (original) The article of manufacture of claim 209, wherein said acid is an organic acid.

213. (original) The article of manufacture of claim 209, wherein said acid is a mineral acid.

214. (original) The article of manufacture of claim 212, wherein said acid is acetic acid.

215. (original) The article of manufacture of claim 212, wherein said acid is citric acid.

216. (original) The article of manufacture of claim 215, wherein said citric acid is anhydrous.

217. (original) The article of manufacture of claim 215, wherein said citric acid is monohydrous.

218. (original) The article of manufacture of claim 215, wherein said citric acid is hydrous.

16

Docket No. NPB-100D5
Serial No. 09/970,558

219. (original) The article of manufacture of claim 210, wherein said acid is an organic acid.
220. (original) The article of manufacture of claim 210, wherein said acid is a mineral acid.
221. (original) The article of manufacture of claim 219, wherein said acid is acetic acid.
222. (original) The article of manufacture of claim 219, wherein said acid is citric acid.
223. (original) The article of manufacture of claim 222, wherein said citric acid is anhydrous.
224. (original) The article of manufacture of claim 222, wherein said citric acid is monohydrous.
225. (original) The article of manufacture of claim 222, wherein said citric acid is hydrous.
226. (original) The article of manufacture of claim 211, wherein said acid is an organic acid.
227. (original) The article of manufacture of claim 211, wherein said acid is a mineral acid.
228. (original) The article of manufacture of claim 226, wherein said acid is acetic acid.
229. (original) The article of manufacture of claim 226, wherein said acid is citric acid.
230. (original) The article of manufacture of claim 229, wherein said citric acid is anhydrous.
231. (original) The article of manufacture of claim 229, wherein said citric acid is monohydrous.
232. (original) The article of manufacture of claim 229, wherein said citric acid is hydrous.
233. (original) An article of manufacture produced by the process of:
- (a) obtaining a sealable container;
 - (b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable

carrier, and an acid; said formulation being such that the formulation comprises no more than 2.3% total impurities when said formulation is stored at 40°C for seven days;

- (c) placing said pharmaceutical formulation in said scalable container;
 - (d) sealing said scalable container; and
 - (e) storing said pharmaceutical formulation in said sealed container for at least seven days;
- wherein said formulation comprises not more than 2.3% total impurities.

234. (original) The article of manufacture of claim 233, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.

235. (original) The article of manufacture of claim 234, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

236. (original) The article of manufacture of claim 233, wherein said acid is an organic acid.

237. (original) The article of manufacture of claim 233, wherein said acid is a mineral acid.

238. (original) The article of manufacture of claim 236, wherein said acid is acetic acid.

239. (original) The article of manufacture of claim 236, wherein said acid is citric acid.

240. (original) The article of manufacture of claim 239, wherein said citric acid is anhydrous.

241. (original) The article of manufacture of claim 239, wherein said citric acid is monohydrous.

242. (original) The article of manufacture of claim 239, wherein said citric acid is hydrous.

243. (original) The article of manufacture of claim 234, wherein said acid is an organic acid.

244. (original) The article of manufacture of claim 234, wherein said acid is a mineral acid.

18

Docket No. NPB-100D5
Serial No. 09/970,558

245. (original) The article of manufacture of claim 243, wherein said acid is acetic acid.

246. (original) The article of manufacture of claim 243, wherein said acid is citric acid.

247. (original) The article of manufacture of claim 246, wherein said citric acid is anhydrous.

248. (original) The article of manufacture of claim 246, wherein said citric acid is monohydrous.

249. (original) The article of manufacture of claim 246, wherein said citric acid is hydrous.

250. (original) The article of manufacture of claim 235, wherein said acid is an organic acid.

251. (original) The article of manufacture of claim 235, wherein said acid is a mineral acid.

252. (original) The article of manufacture of claim 250, wherein said acid is acetic acid.

253. (original) The article of manufacture of claim 250, wherein said acid is citric acid.

254. (original) The article of manufacture of claim 253, wherein said citric acid is anhydrous.

255. (original) The article of manufacture of claim 253, wherein said citric acid is monohydrous.

256. (original) The article of manufacture of claim 253, wherein said citric acid is hydrous.

257-304 (cancelled)

305. (previously presented) A pharmaceutical paclitaxel composition having improved stability comprising: paclitaxel;
polyethoxylated castor oil; and
an acid;
said acid improving the stability of the paclitaxel as compared to an identical composition without

said acid; and

wherein said acid-containing paclitaxel composition is such that at least 97.5% of the paclitaxel potency is retained when the composition is stored at 40° C for 7 days.

306. (previously presented) The pharmaceutical paclitaxel composition of claim 305, further comprising ethanol.

307. (previously presented) The pharmaceutical paclitaxel composition of claim 305, wherein said acid is an organic acid.

308. (previously presented) The pharmaceutical paclitaxel composition of claim 305, wherein said acid is a mineral acid.

309. (previously presented) The pharmaceutical paclitaxel composition of claim 307, wherein said acid is citric acid.

310. (previously presented) The pharmaceutical paclitaxel composition of claim 309, wherein said citric acid is monohydrous.

311. (previously presented) The pharmaceutical paclitaxel composition of claim 309, wherein the citric acid is hydrous.

312. (previously presented) The pharmaceutical paclitaxel composition of claim 309, wherein the citric acid is anhydrous.

313. (previously presented) The pharmaceutical paclitaxel composition of claim 307, wherein said acid is acetic acid.

314. (previously presented) The pharmaceutical paclitaxel composition of claim 306, wherein said acid is an organic acid.

315. (previously presented) The pharmaceutical paclitaxel composition of claim 306, wherein said acid is a mineral acid.

316. (previously presented) The pharmaceutical paclitaxel composition of claim 314, wherein said acid is citric acid.

317. (previously presented) The pharmaceutical paclitaxel composition of claim 316, wherein said citric acid is monohydrous.

318. (previously presented) The pharmaceutical paclitaxel composition of claim 316, wherein the citric acid is hydrous.

319. (previously presented) The pharmaceutical paclitaxel composition of claim 316, wherein the citric acid is anhydrous.

320. (previously presented) The pharmaceutical paclitaxel composition of claim 314, wherein said acid is acetic acid.

321. (previously presented) An improved pharmaceutical paclitaxel composition, said composition comprising as ingredients paclitaxel;
polyethoxylated castor oil; and ethanol;
the improvement comprising an acid mixed with said ingredients such that the stability of the paclitaxel composition is improved as compared to the same paclitaxel composition without said acid; and
said improved paclitaxel composition being such that at least 97.5% of the paclitaxel potency is retained when said composition is stored at 40° C for 7 days.

322. (previously presented) The improved pharmaceutical paclitaxel composition of claim 321, said composition being substantially free of water.

323. (previously presented) The improved pharmaceutical paclitaxel composition of claim 322,

21

Docket No. NPB-100D5
Serial No. 09/970,558

wherein said acid is an organic acid.

324. (previously presented) The improved pharmaceutical paclitaxel composition of claim 322, wherein said acid is a mineral acid.

325. (previously presented) The improved pharmaceutical paclitaxel composition of claim 323, wherein said acid is citric acid.

326. (previously presented) The improved pharmaceutical paclitaxel composition of claim 325, wherein said citric acid is monohydrous.

327. (previously presented) The improved pharmaceutical paclitaxel composition of claim 325, wherein the citric acid is hydrous.

328. (previously presented) The improved pharmaceutical paclitaxel composition of claim 325, wherein the citric acid is anhydrous.

329. (previously presented) The improved pharmaceutical paclitaxel composition of claim 323, wherein said acid is acetic acid.

330. (previously presented) A pharmaceutical paclitaxel composition consisting essentially of:
paclitaxel;

polyethoxylated castor oil;

ethanol; and

an acid;

said acid being in sufficient amount to confer improved paclitaxel stability to said

composition as compared to the paclitaxel stability in the same composition without said acid; said

pharmaceutical paclitaxel composition being substantially free of water; and

said composition being such that at least 97.5% of the paclitaxel potency is retained when said composition is stored at 40° C for 7 days.

22

Docket No. NPB-100D5
Serial No. 09/970,558

331. (previously presented) The pharmaceutical paclitaxel composition of claim 330, wherein said acid is an organic acid.

332. (previously presented) The pharmaceutical paclitaxel composition of claim 330, wherein said acid is a mineral acid.

333. (previously presented) The pharmaceutical paclitaxel composition of claim 331, wherein said acid is citric acid.

334. (previously presented) The pharmaceutical paclitaxel composition of claim 333, wherein said citric acid is monohydrous.

335. (previously presented) The pharmaceutical paclitaxel composition of claim 333, wherein the citric acid is hydrous.

336. (previously presented) The pharmaceutical paclitaxel composition of claim 333, wherein the citric acid is anhydrous.

337. (previously presented) The pharmaceutical paclitaxel composition of claim 332, wherein said acid is acetic acid.

338. (previously presented) An article of manufacture comprising a sealed container and a pharmaceutical paclitaxel composition disposed within said sealed container, said pharmaceutical paclitaxel composition being substantially free of water and comprising:

paclitaxel;

polyethoxylated castor oil;

ethanol; and

an acid;

said acid being in sufficient amount to confer improved paclitaxel stability to said composition as compared to the same composition without said acid; and

23

Docket No. NPB-100D5
Serial No. 09/970,558

said composition being such that at least 97.5% of the paclitaxel potency is retained when said composition is stored at 40° C for seven days.

339. (previously presented) The article of manufacture of claim 338, wherein said acid is an organic acid.

340. (previously presented) The article of manufacture of claim 338, wherein said acid is a mineral acid.

341. (previously presented) The article of manufacture of claim 339, wherein said acid is acetic acid.

342. (previously presented) The article of manufacture of claim 339, wherein said acid is citric acid.

343. (previously presented) The article of manufacture of claim 342, wherein said citric acid is anhydrous.

344. (previously presented) The article of manufacture of claim 342, wherein said citric acid is monohydrous.

345. (previously presented) The article of manufacture of claim 342, wherein said citric acid is hydrous.

346. An article of manufacture produced by the process of:

- (a) obtaining a sealable container;
- (b) obtaining a pharmaceutical formulation consisting essentially of paclitaxel, polyethoxylated castor oil, ethanol, and an acid; said acid being in sufficient amount such that the paclitaxel stability in said formulation is improved as compared to the stability of paclitaxel in the same formulation without said acid, and said acid-containing formulation being such that at least 97.5% of the paclitaxel potency is retained when said formulation is stored at 40° C for seven days;
- (c) placing said pharmaceutical formulation in said sealable container;

- (d) sealing said scalable container; and
- (e) storing said pharmaceutical formulation in said sealed container for at least seven days.

347. (previously presented) The article of manufacture of claim 346, wherein said acid is an organic acid.

348. (previously presented) The article of manufacture of claim 346, wherein said acid is a mineral acid.

349. (previously presented) The article of manufacture of claim 347, wherein said acid is acetic acid.

350. (previously presented) The article of manufacture of claim 347, wherein said acid is citric acid.

351. (previously presented) The article of manufacture of claim 350, wherein said citric acid is anhydrous.

352. (previously presented) The article of manufacture of claim 350, wherein said citric acid is monohydrous.

353. (previously presented) The article of manufacture of claim 350, wherein said citric acid is hydrous.

354. (previously presented) A pharmaceutical paclitaxel composition which is at least 7 days old, consisting essentially of:

paclitaxel;

polyethoxylated castor oil;

ethanol; and

an acid;

said acid being in sufficient amount such that the paclitaxel stability of said composition is improved as compared to the paclitaxel stability of an identical composition without said acid; and

25

Docket No. NPB-100D5

Serial No. 09/970,558

said at least 7-day-old composition being such that at least 97.5% of the original paclitaxel potency is retained.

355. (previously presented) A pharmaceutical paclitaxel composition of claim 354, wherein said acid is an organic acid.

356. (previously presented) A pharmaceutical paclitaxel composition of claim 354, wherein said acid is a mineral acid.

357. (previously presented) A pharmaceutical paclitaxel composition of claim 355, wherein said acid is acetic acid.

358. (previously presented) A pharmaceutical paclitaxel composition of claim 355, wherein said acid is citric acid.

359. (previously presented) A pharmaceutical paclitaxel composition of claim 358, wherein said citric acid is anhydrous.

360. (previously presented) A pharmaceutical paclitaxel composition of claim 358, wherein said citric acid is monohydrous.

361. (previously presented) A pharmaceutical paclitaxel composition of claim 358, wherein said citric acid is hydrous.

362-369 (canceled)